Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

  • Andrew Blauvelt*
  • , Kristian Reich
  • , Tsen Fang Tsai
  • , Stephen Tyring
  • , Francisco Vanaclocha
  • , Külli Kingo
  • , Michael Ziv
  • , Andreas Pinter
  • , Ronald Vender
  • , Sophie Hugot
  • , Ruquan You
  • , Marina Milutinovic
  • , Diamant Thaçi
  • *Korrespondierende/r Autor/-in für diese Arbeit
  • Oregon Medical Research Center
  • Dermatologikum Hamburg and SCIderm Research Institute
  • National Taiwan University Hospital
  • Baylor College of Medicine
  • Hospital 12 de Octubre
  • University of Tartu
  • Emek Medical Center
  • Johann Wolfgang Goethe-Universität
  • Hamilton Health Sciences
  • Novartis Pharma AG
  • Novartis Beijing Novartis Pharma Co Ltd

Abstract

Background Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis. Objective To compare the efficacy and safety of secukinumab and ustekinumab use over 52 weeks. Methods Analysis of 52-week data from CLEAR, a randomized, double-blind, phase 3b study. Results Among 676 randomized subjects, secukinumab demonstrated superiority to ustekinumab at week 52 in the proportion of subjects with ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) (76% vs 61% [P < .0001]); PASI 100 responses were 46% versus 36% (P = .0103) and Investigator's Global Assessment responses of clear/almost clear skin were 80% versus 65% (P < .0001). Subjects on secukinumab reported greater reductions in psoriasis-related pain, itching, and scaling, and greater improvement across all quality-of-life measures evaluated (Dermatology Life Quality Index [DLQI], EuroQoL 5-Dimension Health Questionnaire, Work Productivity and Activity Impairment Questionnaire-Psoriasis, and Health Assessment Questionnaire-Disability Index). At week 52, 72% of subjects on secukinumab versus 59% on ustekinumab (P = .0008) reported no impact of skin disease on their lives (DLQI 0/1 response). Safety and tolerability was comparable. Limitations There was no placebo arm. Conclusion In this head-to-head, double-blind study, secukinumab demonstrated sustained superior efficacy in comparison with ustekinumab in clearing skin through week 52, greater improvement in quality of life, and a favorable and comparable safety profile.

OriginalspracheEnglisch
ZeitschriftJournal of the American Academy of Dermatology
Jahrgang76
Ausgabenummer1
Seiten (von - bis)60-69.e9
ISSN0190-9622
DOIs
PublikationsstatusVeröffentlicht - 01.01.2017

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren